Description
The standardized extract of Devil's Claw (Harpagophytum procumbens), the southern African tuber traditionally used for joint pain and digestive complaints. Standardized to harpagoside content, the principal iridoid glycoside active. Used in joint-support and anti-inflammatory dietary supplements globally.
Light brown to brown free-flowing powder with characteristic bitter taste. Highly water-soluble.
We supply food-grade Devil's Claw Extract from manufacturers in China holding ISO, Halal, Kosher and other certifications relevant to the product and production.
Common market grades include 1.5 percent Harpagoside (the workhorse pharmaceutical-equivalent grade matching the European Medicines Agency monograph specifications), 3 percent Harpagoside (premium grade), 5 percent Harpagoside (high-end concentrated grade), and 4:1 to 10:1 unstandardized ratio extracts.
Bulk and reduced-MOQ shipments. Batch-level COA covering harpagoside content (HPLC), total iridoid glycosides, residual solvents, heavy metals, pesticides, and microbiology.
Introduction
Devil's Claw is a tuber-producing plant native to the Kalahari Desert and surrounding regions of southern Africa, where the indigenous San and Khoi peoples used the root for joint pain, digestive complaints, and fever. The plant's common name reflects the distinctive hooked claw-like seed pods. Commercial development as a herbal medicine began in Germany in the 1950s following anecdotal reports from German colonial settlers.
Industrial production proceeds by ethanol or hydroalcoholic extraction of dried Devil's Claw secondary tubers (the primary tubers are reserved for regeneration), followed by purification and standardization to defined harpagoside content. Sustainable wild-harvest sourcing has emerged as a quality and ethical differentiator.
Regulated as a prescription herbal medicine in Germany and several other European markets; sold as a dietary supplement in the U.S. and most other markets. The European Medicines Agency has issued monographs supporting use for symptomatic relief of minor articular pain and digestive complaints.
Clinical evidence supports modest joint-pain reduction at appropriate doses, with effects comparable to nonprescription NSAIDs in some controlled trials for mild-to-moderate osteoarthritis.
Strategic positioning is dominated by joint-support dietary supplements globally, with strong veterinary applications and established pharmaceutical use in selected European markets.
Where it is used
- Joint-support dietary supplements: osteoarthritis and joint-pain-positioned formulations (the dominant commercial application)
- Anti-inflammatory and pain-management supplement formulations
- Pharmaceutical applications: licensed herbal medicine in Germany, France, and several other European markets
- Combination joint-support formulations with glucosamine, chondroitin, and other joint actives
- Sports nutrition: recovery and anti-inflammatory-positioned products
- Traditional African herbal medicine product formulations
- Veterinary applications: joint-support for horses and senior companion animals (a substantial commercial segment)
- Digestive-support supplement formulations (the traditional use)
Technical data
| Item | Specification |
|---|---|
| Appearance | Light brown to brown free-flowing powder |
| Harpagoside content (HPLC) | 1.5% / 3% / 5% (grade dependent) |
| Total iridoid glycosides | ≥ 2.5% |
| Loss on drying | ≤ 5.0% |
| Residue on ignition | ≤ 8.0% |
| Heavy metals (as Pb) | ≤ 2 mg/kg |
| Total plate count | ≤ 10000 cfu/g |
| Source | Harpagophytum procumbens dried secondary tubers |
Ready to discuss business?
Send us your spec and requirement. We will respond with availability and pricing within 24 hours.